A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury
详细信息 查看全文
- 作者：Shingo Odaa ; shingo61@med.nagoya-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Kentaro Matsuob ; Akira Nakajimaa ; Tsuyoshi Yokoia
- 关键词：AR ; adverse reaction ; BBW ; black box warning ; CCL2 ; chemokine (C-C motif) ligand 2 ; CXCL8 ; chemokine (C-X-C motif) ligand 8 ; DAMP ; damage-associated molecular pattern ; DILI ; drug-induced liver injury ; DMSO ; dimethyl sulfoxide ; FBS ; fetal bovine serum ; FDA ; the U.S. Food and Drug Administration ; GAPDH ; glyceraldehyde 3-phosphate dehydrogenase ; GSH ; glutathione ; IL ; interleukin ; LTKB-BD ; the liver toxicity knowledge base benchmark dataset ; MCP-1 ; monocyte chemoattractant protein 1 ; NLRP3 ; NACHT ; L
- 刊名：Toxicology Letters
- 出版年：2016
- 出版时间：22 January 2016
- 年：2016
- 卷：241
- 期：Complete
- 页码：60-70
- 全文大小：1174 K
文摘
- •
Drug-induced liver injury (DILI) is a major safety problem in drug development.
- •
A novel cell-based assay was developed based on immune and inflammatory factors and drug metabolism to detect drugs with a propensity to cause DILI.
- •
The IL-1β, IL-8, and S100A9 mRNA levels were acceptable indicators for the risk assessment of DILI.
- •
An integrated score of the three factors showed a superior discriminative ability.
- •
Our method considering immune and inflammatory factors and drug metabolism is useful for detecting DILI-positive drugs.